Optimal time to surgery following neoadjuvant chemotherapy and its effect on the survival of patients with breast cancer
- B. Srinivas Pedamallu
- Delilah Hassanally
- Abdul Kasem
- Charlotte Abson
- Ibrahim Ahmed
Affiliations: Department of Oncoplastic Breast Surgery, Kings College Hospitals NHS Trust, Princess Royal University Hospital, Orpington BR6 8ND, UK, Department of Oncoplastic Breast Surgery, Medway Hospitals NHS Trust, Medway Hospital, Gillingham, Kent ME7 5NY, UK, Department of Medical Oncology, Medway Hospitals NHS Trust, Medway Hospital, Gillingham, Kent ME7 5NY, UK
- Published online on: December 13, 2021 https://doi.org/10.3892/wasj.2021.140
Copyright: © Pedamallu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
There is currently an ongoing debate regarding the time to surgery (TS) following neoadjuvant chemotherapy in patients with breast cancer and its effect on survival outcomes. There are three retrospective studies suggesting that the ideal interval is as low as 21 days, 40 days and up to 8 weeks. To date, to the best of our knowledge, there is no consensus available on the ideal time interval to surgery following neoadjuvant chemotherapy in breast cancer patients in the published literature. The present study aimed to evaluate the influence of TS of ≥28 days and its effect on survival outcomes. For this purpose, patients with breast cancer (n=61), during the time period between January, 2012 and December, 2016, were categorised into two cohorts based on the TS following the completion of neoadjuvant chemotherapy. Patients in group 1 (n=8) had a TS of ≤28 days, and those in group 2 had a TS of ≥29 days (n=53). Overall survival and locoregional recurrence‑free survival were compared between both groups. A total of 61 patients with breast cancer who had received neoadjuvant chemotherapy followed by surgery and fulfilled the inclusion criteria were included in the study. The median follow‑up time was 29 months. There was no observed association between age, tumour biology, the chemotherapy regimen, type of surgery, pathological response and the TS. The mortality rates were zero in group 1 and 18.9% in group 2. Locoregional recurrence rates were zero in group 1 and 9.4% in group 2. On the whole, the findings of the present study support a shorter duration (≤28 days) of TS following neoadjuvant chemotherapy for optimal survival outcomes.